VSTM, US92337C2035

Jefferies raises target for Verastem Oncology stock from USD 11.00 to USD 13.00

Published on 10/18/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

VS-7375 posted a 50.00 percent response rate on October 14, 2026. For Verastem Oncology stock, the financing totals USD 250.00 million.

Clinical data and key dates

Jefferies raised its Verastem target from USD 11.00 to USD 13.00 on October 14, 2026.
VS-7375 produced a 50.00 percent confirmed response rate in second-line pancreatic cancer on October 7, 2026.
Verastem is scheduled to report third-quarter 2026 results on November 11, 2026.

VSTM, US92337C2035, Illustration mit AI erstellt.

Jefferies raised its target for Verastem Oncology stock from USD 11.00 to USD 13.00 on October 14, 2026, according to MarketBeat. The move followed new clinical data and a USD 250.00 million financing announced by Verastem Oncology.

Three events reset the story

On June 16, 2026, Verastem dosed the first patient in its TARGET-D 201 study, according to Verastem Oncology. On August 6, 2026, second-quarter revenue reached USD 40.08 million, while the net loss was USD 34.67 million.

On October 14, 2026, Verastem reported a 50.00 percent confirmed objective response rate for VS-7375 at 900 milligrams once daily in second-line pancreatic cancer, based on four responses among eight patients as of the October 7, 2026 data cutoff. The broader second-line-or-later group posted a 41.00 percent response rate among 22 patients, according to Verastem Oncology.

What does the financing change?

The October 14 offering priced 30,937,500 common shares at USD 8.00 each, alongside pre-funded warrants for 312,503 shares. Gross proceeds were expected to reach USD 250.00 million, providing capital for VS-7375 development and general corporate purposes, according to Business Wire. The financing also increases the share count, making clinical execution and future data important counterweights to the added cash.

Dates for the next checkpoints

Verastem is scheduled to report third-quarter 2026 results on November 11, 2026, according to The Wall Street Journal. A second company date is January 1, 2027, when Michael P. Bailey is scheduled to become president and chief executive officer, succeeding Daniel Paterson, as reported by Verastem Oncology.

Pipeline progress meets execution risk

Verastem plans to open a first-line metastatic pancreatic cancer Phase 3 trial by the end of 2026. The company also expects mature data from additional VS-7375 cohorts through 2027, while the October financing gives the program a larger funding base.

The further course of trading is shown by the continuously updated real-time quote of Verastem Oncology stock.